Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apyx Medical CorpBVX · Entity 6609 | Chief Financial Officer | January 04, 2018 | January 11, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apyx Medical Corp
Report date January 04, 2018 · Filed January 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Option to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.59 · Expires 2028-01-03 | Direct | 30,000 |
Reported balance
After 2018-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-04 · Grant · Acquired 30,000 · Balance 30,000 F1: Reporting person was granted a stock option which shall vest ratably over a forty-eight (48) month period and shall become fully vested and fully exercisable on the fourth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person was granted a stock option which shall vest ratably over a forty-eight (48) month period and shall become fully vested and fully exercisable on the fourth anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2018 Filed Jan 11, 2018 16:29 UTC | Apyx Medical Corp BVX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 30,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0000719135-18-000004 · wf-form4_151568812504316.xml · derivative · entry 1 Ewers Jay D. · CIK 0001656070 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-01-03 F1 · derivative.exercise_price: Reporting person was granted a stock option which shall vest ratably over a forty-eight (48) month period and shall become fully vested and fully exercisable on the fourth anniversary of the date of grant. F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a forty-eight (48) month period and shall become fully vested and fully exercisable on the fourth anniversary of the date of grant. Read SEC document |
| May 01, 2017 Filed Sep 27, 2017 13:15 UTC | Apyx Medical Corp BVX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 70,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0000719135-17-000055 · wf-form4_150651808933423.xml · derivative · entry 1 Ewers Jay D. · CIK 0001656070 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-04-30 F1 · derivative.exercise_price: Reporting person was granted a stock option which shall vest ratably over a forty-eight (48) month period and shall become fully vested and fully exercisable on the fourth anniversary of the date of grant. F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a forty-eight (48) month period and shall become fully vested and fully exercisable on the fourth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.